Navigation Links
Varian Medical Systems Selected to Supply Major Project to Bring Advanced Radiotherapy Treatments to North of Portugal
Date:10/30/2009

PORTO, Portugal, Oct. 30 /PRNewswire-FirstCall/ -- Cancer patients in northern Portugal will gain access to advanced cancer treatments with the acquisition of seven new treatments machines from Varian Medical Systems (NYSE: VAR) by the Instituto Portugues Oncologia, IPO Porto. The order, placed in August, includes the country's first Novalis Tx(TM) device for advanced radiosurgery and two Trilogy® medical linear accelerators offering RapidArc® radiotherapy capability.

The project involves complete reconstruction of an institute that first began treating cancer patients in 1974 and has offered top quality cancer care for north Portugal's 3.6m inhabitants since. Four Clinac® DHX linear accelerators, ARIA(TM) oncology information software with 64 workstations and 15 treatment planning systems also form part of the largest single radiotherapy order ever placed in Portugal. Varian has also signed an eight-year service contract with the institute.

"The efficacy of radiotherapy treatments is already very well known but the improvement in quality that will come from this project will be of enormous benefit to the quality of life of patients in the north of Portugal," said Helena Pereira, M.D., IPO's radio oncology service medical director. "This new equipment will allow us to introduce new radiation delivery techniques that offer more efficient and more precise ways of treating cancer while reducing side effects."

Laranja Pontes, M.D., the Institute's CEO, added, "We have been working with Varian for twenty years and we are very pleased with the relationship. The acquisition of this new equipment shows our faith in this relationship and our belief that Varian's equipment and software offer our patients the best treatments."

RapidArc delivers a precise and efficient treatment in single or multiple arcs of the treatment machine around the patient and makes it possible to deliver image-guided intensity modulated radiotherapy (IMRT) two to eight times faster than is possible with conventional IMRT. Faster treatments allow for greater precision, since there is less chance of patient or tumor movement during treatment delivery and, with less time on the treatment couch, also allow for greater patient comfort.

Novalis Tx from Varian and BrainLAB features very high dose delivery rates, which contributes to shorter treatment times. It also offers dynamic fine beam shaping using the HD-120 high definition multi-leaf collimator (MLC) and non-invasive, precise patient positioning. The integrated On-Board Imager® device pinpoints the target and enables positioning of the patient with millimeter precision.

"This is a bold and impressive project and we are delighted that IPO Porto has selected Varian equipment and software to equip it," says Michael Sandhu, head of Varian's Oncology Systems business in Europe. "When clinical treatments start, this equipment will make a huge difference to cancer patients in the region, not only in additional treatment machines but also in the use of more efficient procedures."

IPO Porto is a public health institution of international renown in the treatment, research and teaching of cancer, often treating the most complex cancer cases in the north of the country. In 2008, almost 3,000 new cancer patients were treated at the institute.

Editorial contact: Neil Madle, Varian Medical Systems, +44 7786 526068

About Varian Medical Systems

Varian Medical Systems, Inc., of Palo Alto, California, is the world's leading manufacturer of medical devices and software for treating cancer and other medical conditions with radiotherapy, radiosurgery, proton therapy, and brachytherapy. The company supplies informatics software for managing comprehensive cancer clinics, radiotherapy centers and medical oncology practices. Varian is a premier supplier of tubes and digital detectors for X-ray imaging in medical, scientific, and industrial applications and also supplies X-ray imaging products for cargo screening and industrial inspection. Varian Medical Systems employs approximately 5,100 people who are located at manufacturing sites in North America, China, and Europe and in its 79 sales and support offices around the world. For more information, visit http://www.varian.com/

About IPO Porto

The Portuguese Oncology Institute, Porto Francisco Gentil (IPOP) was created in 1974. Its radiotherapy department has been treating non-stop for 35 years. IPOP's main mission is to deliver high quality, humanist and efficient oncology healthcare to the population of north Portugal. It also has a goal of developing innovative research, training and teaching methods within oncology. For more information, visit www.ipoporto.pt

SOURCE Varian Medical Systems, Inc.


'/>"/>
SOURCE Varian Medical Systems, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Varian Medical Systems to Exhibit a Wide Selection of Flat Panel X-Ray Image Detectors and X-Ray Tubes at the CMEF Show in Chengdu, China
2. Varian, Inc. Delivers a Productivity Increase of Up to 100% With Its 710-ES Series ICP-OES
3. Farletuzumab Data Presented on Phase II Clinical Trial in First-Relapsed Ovarian Cancer Subjects
4. NKTR-102 Shows Encouraging Anti-Tumor Activity in Ovarian Cancer in Phase 1 and Preclinical Data Presented at the ECCO 15 and 34th ESMO Multidisciplinary Congress
5. Pivotal Registration Trial of OPAXIO Maintenance Therapy in First-Line Ovarian Cancer Reaches Enrollment Milestone of 600 patients, Cell Therapeutics and the Gynecologic Oncology Group Discuss Potential for Early Interim Analysis
6. FDA Clears a Test for Ovarian Cancer
7. Cancer Treatment Centers of America(R) Studies Treatment That Aims Chemotherapy Directly at Ovarian Cancer Cells
8. Oasmia: FDA Grants Paclical(R) Orphan Drug Designation for Ovarian Cancer in the USA
9. Varian Medical Systems to Exhibit Cancer Treatment and X-ray Imaging Technologies at China Med Exhibition
10. Access Pharmaceuticals Announces Positive ProLindac(TM) Phase 2 Ovarian Cancer Clinical Trial Results
11. Pivotal Data Published For First Biomarker Combination Test to Determine Risk of Ovarian Cancer in Women Who Present With Pelvic Mass
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/27/2016)... Tie-up with Government hospitals as ... to save newborns   Fortis La Femme, ... collaboration with Breast Milk Foundation (BMF), a non-profit organization within ... Bank, ,Amaara, in Delhi-NCR today. This non-profit centre recognizes that ... and should be available to babies deprived of mother,s milk.  ...
(Date:4/27/2016)... April 27, 2016 Oasmia ... developer of a new generation of drugs within ... survival results for Paclical/Apealea in the Phase III ... with epithelial ovarian cancer. These preliminary results showed ... combination with carboplatin versus Taxol in combination with ...
(Date:4/26/2016)... , April 26, 2016 Diplomat Pharmacy, ... of Jennifer Hagerman , Pharm D., to Vice ... growing role at Diplomat, Hagerman will continue to lead ... company that delivers custom education and training to Diplomat ... specialty pharmacy industry. Diplomat University also houses the quality ...
Breaking Medicine Technology:
(Date:4/29/2016)... ... ... Dr. Robert Mondavi, one of the dentists in Torrance , is now ... as more patients are discovering the many different ways they can change and improve ... to them and which ones might work for their smiles. , “One of ...
(Date:4/29/2016)... ... April 29, 2016 , ... Reltok Nasal Products proudly announces that Boston ... and neck/ear, nose and throat specialty, has added the KOTLER NASAL AIRWAY™ to its ... is a newly patented safety device secured by nasal surgeons onto the floor ...
(Date:4/29/2016)... ... April 29, 2016 , ... Jvion, the market ... funding led by Eastside Partners, with participation from existing investor Martin Ventures. ... and accelerate its technology and product roadmap. , “Jvion is experiencing ...
(Date:4/29/2016)... ... April 29, 2016 , ... Regenerative Medicine Solutions (RMS) scored ... satisfaction survey, earning them second place for Tampa’s Best Places to Work. They were ... “This is a great accomplishment for our team,” says RMS Human Resources Manager Irene ...
(Date:4/29/2016)... Newport Beach, CA (PRWEB) , ... April 29, 2016 , ... ... Dr. Jane L. Frederick, Dr. Sanaz Ghazal, and Dr. Daniel A. Potter -- are ... the Society for Assisted Reproductive Technology (SART). In April, SART published the ...
Breaking Medicine News(10 mins):